MicroRNAs Predict Pancreatic Cancer Risk Years in Advance
Expression levels of several microRNAs in plasma samples can help predict the onset of pancreatic cancer up to 5 years prior to clinical diagnosis.
Source: medscape.com
Screening Trial News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Screening Trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Screening Trial Today - Breaking & Trending Today
GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology A
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced the 65th American Society of Hematology (ASH) Annual Meeting will feature two presentations o...
Source: pharmiweb.com
GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia
GlycoMimetics, Inc. , a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced the 65th American...
Source: marketscreener.com
Kura Oncology's Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society's Pediatric Acute Leukemia (PedAL) Master Clinical Trial -December 08, 2023 at 07:30 am EST
SAN DIEGO, Dec. 08, 2023 -- Kura Oncology, Inc. , a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, and The Leukemia...
Source: marketscreener.com
Kura Oncology's Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society's Pediatric Acute Leukemia (PedAL) Master Clinical Trial
SAN DIEGO, Dec. 08, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, and The Leukemia & Lymphoma Society (LLS), the largest private funder of blood cancer research, today announced a clinical collaboration to evaluate Kura’s menin inhibitor, ziftomenib, in combination with chemotherapy in pediatric patients with relapsed/refractory KMT2A-rearranged, NUP98-
Source: yahoo.com